natgillin/translations-raw huggingface dataset:
Still a further aspect of the present invention is a method for the treatment of a patient having circadian fluctuations in Interleukin 6 levels due to underlying inflammation, which comprises administering to said patient an effective amount of a glucocorticoid contained in a delayed-release dosage form, wherein said treatment is administered once daily for at least about two weeks, and wherein said treatment is administered such that the glucocorticoid is released at or before the time when the patient's Interleukin 6 level is at a daily peak. 
Glukokortikoid sadržan u obliku doziranja s odgođenim otpuštanjem za uporabu u liječenju bolesnika koji imaju dnevne promjene razina interleukina 6 zbog upalne podloge, pri čemu se navedeno liječenje provodi davanjem lijeka jednom dnevno kroz najmanje dva tjedna i pri čemu je oblik doziranja s odgođenim otpuštanjem primijenjen tako da se glukokortikoid otpušta u vrijeme ili prije vremena dnevnog pika bolesnikove razine interleukina 6, npr. između 4 i 8 sati ujutro.
treating the compound of formula (7) with a compound of formula (8) 
(d) obradu spoja formule (7) sa spojem formule (8) o
Pharmaceutical composition comprising a pharmaceutical formulation including an amount of a PDE4 inhibitor, an amount of a HMG-CoA reductase inhibitor and at least one pharmaceutically acceptable auxiliary, wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, a pharmaceutically acceptable salt of ROFLUMILAST, ROFLUMILAST-N-oxide and a pharmaceutically acceptable salt of ROFLUMILAST-N-oxide, the HMG-CoA reductase inhibitor is SIMVASTATIN or a pharmaceutically acceptable salt thereof, and wherein the first amount and the second amount together comprise an effective amount for the preventive or curative treatment of an inflammatory pulmonary disease. 
PATENTNI ZAHTJEVI Farmaceutski sastav, naznačen time, da obuhvaća farmaceutsku formulaciju koja uključuje jednu količinu PDE4- inhibitora, jednu količinu inhibitora reduktaze HMG-CoA i barem jedno farmaceutski prihvatljivo pomoćno sredstvo, dok je PDEA-inhibitor odabran iz skupine koja sadrži ROFLUMILAST, farmaceutski prihvatljivu sol ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljivu sol ROFLUMILAST-N-oksida, gdje inhibitor reduktaze HMG-CoA je SIMVASTATIN ili njegova farmaceutski prihvatljiva sol, pri čemu prva količina i druga količina zajedno sastavljaju djelotvornu količinu za preventivno i kurativno liječenje upalne bolesti pluća.
An isolated fusion protein, the fusion protein comprising an RSV F protein fragment and a non-RSV protein, wherein the RSV F protein fragment consists of amino acids 195 to 228 of SEQ ID NO:1, amino acids 195 to 228 of SEQ ID NO:2, amino acids 1 to 34 of SEQ ID NO:7, or amino acids 1 to 34 of SEQ ID NO:9, wherein the non-RSV protein comprises the squash family protease inhibitor Ecballium elaterium trypsin inhibitor II (EETI-II), wherein the inhibitor loop of EETI-II is replaced by the RSV F protein fragment and wherein the fusion protein is constrained in a conformation that can be specifically bound by monoclonal antibody D25 or an antigen-binding fragment, variant, analog, or derivative thereof. 
Izolirani fuzijski protein, te fuzijski protein sadrži fragment proteina RSV F i ne-RSV protein, pri čemu se fragment proteina RSV F sastoji od aminokiselina 195 do 228 iz SEQ ID NO:1, aminokiselina 195 do 228 iz SEQ ID NO:2, aminokiselina 1 do 34 iz SEQ ID NO:7, ili aminokiselina 1 do 34 iz SEQ ID NO:9, pri čemu ne-RSV protein sadrži inhibitor proteaze obitelji tikvovki Ecballium elaterium inhibitor tripsina II (EETI-II), pri čemu je inhibitorska petlja EETI-II zamijenjena fragmentom proteina RSV F i pri čemu je fuzijski protein ograničen u konformaciji koja se može posebno vezati s monoklonskim antitijelom D25 ili fragmentom koji veže antigen, njegovom varijantom, analogom ili derivatom.
Adding more dopant will make the triggering more difficult and thus slower. 
Dodavanjem više sredstva za dopiranje poticanje će biti teže 1 stoga sporije.
The volume was reduced in vacuo, and water (60 mL) was added. 
Volumen se reducira u vakuumu i doda se voda (60 ml).
an antigen, for use as a medicament in a method of enhancing the humoral and/or cell mediated immune response to the antigen of a subject vaccinated with said vaccine composition, relative to a control from a subject vaccinated with said antigen alone, and wherein the antigen is not complexed with a B subunit of Shiga toxin or a functional equivalent thereof which is able to bind the Gb3 receptor. 
H i b) antigen, naznačen time da je za uporabu kao lijek u postupku poboljšanja humoralnog i/ili stanično posredovanog imunog odgovora na antigen kod subjekta koji je cijepljen s navedenim pripravkom cjepiva, u odnosu na kontrolu kod subjekta koji je cijepljen samo s navedenim antigenom, te pri čemu antigen nije kompleksiran s B podjedinicom Shiga toksina ili njegovim funkcionalnim ekvivalentom koji je sposoban vezati se na Gb3 receptor.
Use according to claim 7 wherein the respiratory disease is asthma or chronic obstructive pulmonary disease (COPD). 
Uporaba u skladu s patentnim zahtjevom 10, naznačena time, da je bolest dišnih putova astma ili kronična opstruktivna bolest pluća (COPD).
The oxycodone hydrochloride composition of any one of claims 5 to 11, wherein in the process the reduction is carried out in a solvent, preferably in an alcohol, more preferably an alcohol selected from the group consisting of methanol, ethanol and isopropanol; or in a combination of isopropanol and water. 
Postupak prema zahtjevu 3, naznačen time da je otapalo izabrano iz skupine koja sadrži vodu, izopropanol, metanol, etanol, te odgovarajuću smjesu bilo koja dva ili više od navedenih otapala. Postupak prema zahtjevu 4, naznačen time da je otapalo kombinacija izopropanola i vode.
diluting a solution comprising gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate and a polar aprotic solvent with an aqueous vehicle to provide a formulation for infusion or injection; and administering the formulation for infusion or injection to the subject by infusion or injection. 
Postupak za pripremu farmaceutske formulacije gemcitabin-[feml-benzoksi-L-alaninil)]-fosfata koji je pogodan za infuziju ili injekciju, pri čemu postupak sadrži: razblaženje rastvora koji sadrži gemcitabin-[fenil-benzoksi-L-alaninil)]-fosfat i dimetil acetamid sa vodenim nosačem da bi se dobila formulacija pogodna za infuziju ili injekciju.
Positive symptoms, such as hallucinations and delusions, can occur when overactivity of dopamine in the mesolimbic tract occurs. 
Pozitivni simptomi, poput halucinacija 1 iluzija, se mogu zbivati kada dolazi do prekomjernog djelovanja dopamina u mezolimbičnom traktu.
represents hydrogen, 
Rs predstavlja vodik,
The method according to claim 1, wherein said ionizing electromagnetic radiation is selected from the group consisting of X-rays and Y-rays. 
Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu su navedena ionizirajuća zračenja odabrana iz grupe koja se sastoji od X-zračenja, y-zračenja, elektronskih zraka i radioizotopnih emisija.
The subject invention provides crystalline R(+)-N-propargyl-1-aminoindan. The subject invention also provides R(+)-N-propargyl-1-aminoindan characterized by a powder X-ray diffraction pattern having peaks at 8.5, 12.6, 16.1, and 16.9 in degrees two theta ±0.2. 
Kristalni R(+)-N-propargil-1-aminoindan prema patentnom zahtjevu 1, naznačen time, da slika rendgenske difrakcije praha ima pikove na 8,5, 12,6, 16,1, 16,9, 20,3, 20,9, 25,4, 26,4 1 28,3 u stupnjevima dva-teta +0,2.
A compound of formula I, or diastereomers or enantiomers thereof, or pharmaceutically acceptable salts of formula I or diastereomers or enantiomers thereof, or mixtures thereof: wherein: 
Spoj sa formulom I, ili njegovi diastereomeri ili enantiomeri, ili farmaceutski prihvatljive soli sa formulom I ili njihovi diastereomeri ili enantiomeri, ili njihove smjese:
A shaking device (100,200,300,400,800) for harvesting small fruit according to claim 1, wherein, said actuation means comprises a frequency adjustment means configured in such a way that by adjusting said frequency the enhanced amplitude of the oscillations of the sticks is between 1,5 to 10 times larger than the amplitude of the oscillation received from said actuation means, and consequently the harvesting power of the shaking device is adjusted. 
Vibrirajući uređaj za branje malog voća (100, 200, 300, 400) prema zahtjevu 1, pri čemu navedeni aktuator obuhvaća sredstvo za podešavanje frekvencije, koje je konfigurirano tako da se podešavanjem frekvencije na način da štapovi osciliraju s amplitudom 1,5 do 10 puta većom od one koju izaziva aktuator, podešava 1 jačina trešnje kojom uređaj bere voće.
a labelled nucleic acid probe for the pp38 polymorphism specific to virulent strains of MDV-1. 
(ili) obilježenu nukleinskokiselinsku sondu za polimorfizam pp38 specifičnu za virulentne sojeve MDV-1.
is an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, O (oxygen), S (sulfur) or NR11; and 
je po izboru supstituiran cikloalkil, po izboru supstituiran aril, po izboru supstituiran heteroaril, po izboru supstituiran heterociklil, O (kisik), S (sumpor) ili NR11; i
providing, by the third interface (35c), a third segregated data flow for Airlines Operational Communication message exchange between the ground station (35) and the second airline remote station (5); 
- < Pružanje, putem trećeg sučelja (350), trećeg odvojenog protoka podataka za razmjenu poruka zračne operativne komunikacije između zemaljske postaje (35) i druge daljinske zrakoplovne postaje (5);
Plant according to claim 1 wherein said at least one collection tank is adapted to operate under suction. Plant according to claim 1 or 2 wherein said tertiary treatment unit further comprises at least one reverse osmosis filter (21) downstream said ozone treatment module (17). 
Postrojenje u skladu s patentnim zahtjevom 1 ili 2, naznačeno time što navedena jedinica za tercijarnu obradu dodatno sadrži najmanje jedan filtar za povratnu osmozu (21), nizvodno od navedenog modula za obradu ozonom Postrojenje u skladu s patentnim zahtjevom 1 ili 2, naznačeno time što se navedeni najmanje jedan sabirni spremnik sastoji od:
The composition is particularly advantageously used in beverages and foodstuffs that contain at least 10 µg/kg (ppb) riboflavin, more preferably at least 50 µg/kg riboflavin and most preferably at least 100 µg/kg riboflavin. 
Pripravak se naročito korisno upotrebljava u pićima i prehrambenim proizvodima koja sadržavaju najmanje 10 ug/kg (ppb) riboflavina, poželjnije najmanje 50 ug/kg riboflavina i najpoželjnije najmanje 100 ug/kg riboflavina.
In a one embodiment, at least 20% of the oligosacchardies in the Fc region of said polypeptide are nonfucosylated or bisected, nonfucosylated. 
Antitijelo u skladu sa zahtjevom 9, naznačeno time, da najmanje 20% oligosaharida u Fc regiji navedenog polipeptida je dvogekcijsko, ne-fukozilirano.
The blood brain barrier shuttle of claims 10 or 11, wherein the effector entity is a full length antibody directed to alpha synuclein and the monovalent binding entity is one scFab directed to the transferrin receptor. 
Prijenosnik za krvno-moždanu barijeru prema zahtjevima od 4 do 6, naznačen time, da je entitet efektora jedno protutijelo pune duljine usmjereno na alfa sinuklein.
A seed of the plant of claim 1 wherein the seed comprises said DNA encoding said Cry1Ca insecticidal protein and said DNA encoding said Cry1Fa insecticidal protein. 
2. < Sjeme biljke prema zahtjevu 1, naznačeno time, da navedeno sjeme obuhvaća DNK koja kodira insekticidni protein Cry1Ca i DNK koja kodira insekticidni protein Cry 1Fa.
Use, in combination, of a cholestanol derivative represented by formula (1): 
Uporaba, naznačena time, da se primjenjuje kombinacija s derivatom kolastanola predstavljenog formulom (1):
A compound of formula (I) according to claim 1 wherein R1 represents an ethyl group, R2 represents a hydrogen atom, and R3 represents an ethyl group; or a pharmaceutically acceptable salt thereof. 
Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time što R1 predstavlja etilnu skupinu, R2 predstavlja atom vodika, a R3 predstavlja etilnu skupinu; ili njegova farmaceutski prihvatljiva sol.
Particularly suitable are ethanol or isopropanol. 
Naročito poželjni su etanol ili izopropanol.
Use of a compound any of claims 1 to 6 for the preparation of a medicament for the treatment or prophylaxis of obesity, diabetes mellitus, male or female sexual dysfunction and/or erectile dysfunction. 
Upotreba spoja iz bilo kojeg patentnog zahtjeva od 1. do 6., naznačena time da je za pripremu lijeka za liječenje ili za profilaksu pretilosti, diabetesa mellitusa, muške ili ženske seksualne disfunkcije ifili erektilne disfunkcije.
A compound according to claim 1 or 2 having the following formula 
2. - Spoj iz patentnog zahtjeva 1 koji ima formulu:
Thus, the lack of effective therapies for the treatment of drug dependence for both the general population and specifically drug dependent pregnant woman strongly suggests that novel approaches are needed. 
Stoga, nedostatak učinkovitih terapija za liječenje ovisnost o drogi kod o drogi ovisne trudne žene snažno navodi na zaključak da su potrebni novi pristupi.
an edge-reliability obtaining device configured to calculate an index for the each pixel in accordance with the magnitude of the gradient and pixel values surrounding the pixel in the band image; and 
uređaj za dobivanje pouzdanosti rubova (16) koji ima konfiguraciju za izračunavanje indeksa (E) za svaki piksel u skladu s magnitudom gradijenta (m) i vrijednostima piksela koje okružuju piksel u slici na traci (a, B, Y); i
The synthesis of pirfenidone has been worked out. 
POBOLJÅ ANI POSTUPAK ZA SINTEZU PIRFENIDONA
A composition comprising: (1) a compound of formula: 
Spoj iz patentnog zahtjeva 1 koji je spoj formule: aa
The wine decanter device of one or more of the precedings claims 2 to 4, wherein said funnel-shaped receptacle (2) is supported above said pyramidal conveyor (7), with interposition of said cup-shaped receptacle (5) by means of a support vertical structure (4). 
Uređaj za pretakanje vina prema jednom ili više prethodnih zahtjeva 2 do 4, pri čemu je spomenuta ljevkasto oblikovana posuda (2) podržana iznad spomenutog piramidalnog transportera (7) s uvlačenjem spomenute posude (5) oblika šalice uz pomoć noseće vertikalne konstrukcije (4) .
Method according to claim 9, wherein during a dangerous condition the electrically controlled switch (20) is forced open until the same switch (20) is disconnected from the network (10). 
Postupak u skladu sa zahtjevom 9, naznačen time da se za vrijeme opasnih uvjeta elektronski kontrolirana sklopka prisilno otvara, sve dok ta sklopka (20) nije odspojena od mreže (10)
reacting compound (VII) in the presence of molybdenum hexacarbonyl; optionally in the presence of one or more reagents selected from the group consisting of norbornadiene, tetrabutylammonium bromide, and a base selected from triethylamine or DABCO; in an organic solvent selected from the group consisting of diglyme, dioxane, butyronitrile, and propionitrile; followed by the addition of methylamine; at a temperature of about 60° C. to about 140° C.; to yield the corresponding compound (X). 
HR P20190583 T1 reakcije spoja (VII) u prisustvu molibden heksakarbonila; opcionalno u prisustvu jednog ili više reagenasa koji su odabrani iz grupe koja se sastoji od norbornadiena, tetrabutilamonij bromida, i baze koja je izabrana iz trietilamina ii DABCO; u organskom otapalu koje je izabrano iz grupe koja se sastoji od diglima, dioksana, butironitrila, i propionitrila; praćeno dodavanjem metilamina; na temperaturi od oko 60 *C do oko 140 "C; da bi se dobio odgovarajući spoj (X).
and wherein the T cell response achieved following the administration of antibody or PD-1 binding fragment thereof is greater than the T cell response achieved by administering either the antibody or PD-1 binding fragment thereof alone or the potentiating agent alone. 
te pri čemu je odgovor T stanica koji se postiže nakon davanja fuzijskog proteina veći od odgovora T stanica koji se postiže davanjem bilo samog fuzijskog proteina ili samog sredstva za pojačavanje.
A compound of Claim 4, wherein R1 is substituted or unsubstituted heterocyclyl, or substituted or unsubstituted -O-heterocyclyl. 
Spoj prema Zahtjevu 4, naznačen time, da R1 je supstituirani ili nesupstituirani heterociklil, ili supstituirani ili nesupstituirani –O-heterociklil.
Tank according to claim 10 where the means for piercing the tearable membrane of the container and for cooperating with the hopper of the container are a conduit having a section that is smaller than the opened end and larger than the discharge outlet. 
HR P20100639 T1 bušenje pokrova kojeg se može probušiti spremnika i za kooperiranje s lijevkom spremnika je cilindar (10) koji sadrži dio manji od dijela otvorenog kraja (4) spremnika posuda i veći od dijela spremnika izlaz za pražnjenje (6).
The method of claim 7, wherein the compound is represented by the following structural formula: 
Spoj prema zahtjevu 34, pri čemu je spoj prikazan "dona strukturnom formulom:
A test composite material is prepared by mixing 65 vol % of the zirconia particles to be tested and 35 vol % of a polymer resin system (36% (w/w) BisGMA, 43.35% (w/w) UDMA, 20% (w/w) TEGDMA. 
Kompozitni materijal za testiranje je pripravljen miješanjem 65 vol % cestica cirkonijeva oksida koji će biti testirani i 35 vol% sustava polimeme smole (36% (w/w) BisGMA. 43.35% (w/w) UDMA, 20% (ww) TEGDMA.
The volume available for each water molecule is about 15 Å3, which is lower than the usually assumed value of 40 Å3. Due to competitive mechanisms (water hydrogen bonds linking principle molecules vs. a low void volume available for water molecules), crystal structures are partially disordered giving rise to a rationale about the ability of the structure to accommodate different proportions of water molecules without changing the structure. 
Volumen koji je na raspolaganju svakoj molekuli vode je oko 15 A*, što je niže nego što obično podrazumijeva vrijednost od 40 A*, S obzirom na kompetitivne mehanizme (vodene vodikove veze koje povezuju glavne molekule nasuprot malom volumenu koji je na raspolaganju molekulama vode), kristalna je struktura djelomično poremećena što predstavlja 10
A particulate polylactic acid according to any one or more of the preceding claims, characterised in that the polylactic acid comprises a chain extender, preferably selected from the group consisting of polyepoxides and diepoxides, diisocyantates, oxazines and oxazolines, cyclic dianhydrides, organic peroxides and one or more combinations thereof. 
Partikulirana polimliječna kiselina u skladu s bilo kojim od ili više prethodnih patentnih zahtjeva, naznačena time što polimliječna kiselina sadrži produljivač lanca, koji se po mogućnosti bira iz skupine koju čine poliepoksidi i diepoksidi, diizocijanati, oksazini i oksazolini, prstenasti dianhidridi, organski peroksidi 1 jedna ili više njihovih kombinacija.
Consequently, subjective satiety is statistically different between both treatments, i.e. 
Shodno tome, subjektivna je sitost statistički HR P20080446 T3 različita u oba tretmana, tj.
For sanitization, the column was flushed with at least 3 BV of NaOH 0.5 M, incubated for 1 hour at room temperature, and then the column was rinsed with 3 BV of purified water. 
Za sterilizaciju, kolona je oprana s najmanje 3 BV 0.5 M NaOH, inkubirana u trajanju od 1 sata na sobnoj temperaturi, a nakon toga kolona je oprana s 3 BV pročišćene vode.
In some alternately preferred embodiments, the HEMA is present at a range of from about 2% to about 6%, more preferably from about 2% to about 5%, more preferably from about 2% to about 4% by weight of the nail coating composition. 
Pripravak u vidu gel-laka za nokte za čije sušenje se korisiti zračenje, koji sadrži: od 40% do 60% di-[hidroksietil metakril] trimetilheksil dikarbamata; od 3% do 5% najmanje jednog estera metakrilne kiseline; od 3% do 6% hidroksietil metakrilata; od 3% do 6% hidroksipropil metakrilata; od 0,1% do 0,4% fotoinicijatora; 1 boju za lakove za nokte, pri čemu postoci označavaju težinske postotke izražene u odnosu na ukupnu težinu pripravaka.
The juice extraction module according to claim 1, wherein the crushing processing surface (610) is formed with at least one milling blade (630). A juice extraction module for a juicer, comprising: 
Modul za ekstrakciju soka u skladu s patentnim zahtjevom 1, naznačen time što dio za obradu gnječenjem (600) ima površinu za obradu gnječenjem (610), gdje površinu za obradu gnječenjem (610) čini najmanje jedna lopatica za mljevenje (630).
The liquid formulation of claim 1, wherein the salt is the MH2 form of the D-Lactic acid addition salt. 
Tekuća formulacija u skladu s patentnim zahtjevom 1, pri čemu je navedena sol dodatna sol D-mliječne kiseline.
In one embodiment, provided herein are compounds of Formula IX: 
Spoj sukladno zahtjevu 1, naznačen time što ima formulu IX: oi
In an embodiment of this kind, the endless belt, at the beginning of a rolling step, is moved transversely (with respect to the plane of the web) towards the web to contact a smoking article rod fed to the area of the support and, at the end of that rolling step, is moved transversely away from the web to release that wrapped smoking article rod. 
Tolanja, pomiče poprijeko u odnosu na traku (80), kako bi došla u kontakt sa šipkom od proizvoda za pušenje (1) koji je doveden u prostor podloge (20) i na kraju faze rolanja se pomiče poprijeko tako da se udaljava od trake (80), kako bi se na taj način oslobodila omotana šipka od proizvoda za pušenje.
Paragraph 19. The compound of paragraph 15 wherein Z is imidazo[1,2- a]pyridin-2-yl substituted with up to 2 substituents independently selected from C1-4 alkyl, C1-4 alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkyloxy, halogen, alkylsulfonyl and cyano. 
Spoj prema bilo kojem od zahtjeva 1-10, naznačen time da je Z imidazo[1,2-a]piridin-2-il supstituiran s najviše 2 supstituenta nezavisno izabrana iz skupine koju sačinjavaju Ci4 alkil, Cia alkoksi, C3-Cg cikloalkil, C2-Cg cikloalkiloksi, halogen, alkilsulfonil 1 cijano.
Use of adhesive compositions comprising an adhesive polymer and a plasticizer for removing acari, bacteria, moths, ticks, fleas from fabric or animal's hair, characterized in that said plasticizer is contained in an amount in the range of 5-45% based on the weight of the wet compositions. 
Uporaba adhezivnih sastava obuhvaća adhezivni polimer 1 plastifikator za uklanjanje grinja, bakterija, moljaca, krpelja, buha iz tkanine ili krzna životinje, karakterizirana na način da je navedeni plastifikator sadržan u količini u rasponu od 5-45% na temelju težine mokrih sastava.
Mechanism according to claim 3, wherein the columns (14) pass through the moving equipment (31), performing the function of guide in the movement of the moving equipment (31) itself along the vertical axis. 
Mehanizam sukladno zahtjevu 4, pri čemu stupovi (14) prolaze kroz pomičnu opremu (31), izvodeći funkciju vodiča u pokretanju pomične opreme (31) duž vertikalne osi.
Add 8.5 kg of 30% sodium hydroxide solution and if necessary, mike further additions of 30% sodium hydroxide solution until a pH of 6.7 to 7.1 is obtained. 
Dodati 8.5 kg 30% otopinu natrijeva hidroksida ako je neophodno, dalje dodati 30% otopinu natrijeva hidroksida sve dok se dobije pH od 6.7 do 7.1.
wherein X1, X2, R1, A3, L1 and n are as defined above and when L1 is nitro, said nitro group is reduced to an amino group and the amino derivative obtained is then reacted with a compound of formula III G-A4 b -L0 (III), 
(XD) gdje su X1, X2, R1, A3, Ll in definirani kao gore; i kada je LI nitro, navedenu nitro skupinu se reducira u amino skupinu, a dobiveni amino derivat zatim reagira sa spojem formule III G-A4b-L0 (III), gdje